Guanfacine to Reduce Relapse Risk in Women With Alcohol Use Disorder (AUD)

Completed · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Alcohol Abstinence

In brief

Guanfacine may preferentially reduce craving and improve cognitive control in women with Alcohol Use Disorder (AUD), compared to men. As these behaviors are related to relapse, the objectives of this study are to conduct a 10-week out-patient clinical trial to examine the effects of Guanfacine Extended Release (XR; 3mgs) versus placebo on drinking measures in women with AUD.

Key facts

Study ID

NCT03137082

Run by

Stony Brook University

People needed

32

Starts

2017-07-12

Expected to finish

2021-03-31

Last updated by the study team

2024-06-05

Who can join

Age: 18 and older, up to 50. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Must meet Diagnostic and Statistical Manual of Mental Disorders-V (DSM- V) criteria for moderate to severe Alcohol Use Disorder (AUD),
• Must produce positive urine toxicology screens on admission to study
• Must demonstrate good health as verified by screening examination
• Must be able to read English and complete study evaluations
• Must be able to provide informed written and verbal consent

You may not qualify if…

• Meeting current use disorder for any other psychoactive substance, excluding nicotine.
• Having any other current Axis I psychiatric disorders or medical conditions requiring treatment or medication
• EKG evidence at baseline screening of any clinically significant conduction abnormalities including a Bazlett's QTc (corrected QT interval) of >470 msec.
• Must not be on monophasic contraceptives, nursing or pregnant.

Where it is running

• The Health Sciences Center — Stony Brook, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.